Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pregabalin + magnesium sulfate
- Development stage
- Approved
- Lead developer
- Pfizer
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
A combination of pregabalin and magnesium sulfate used as a multimodal analgesic approach for managing postoperative pain. Pregabalin binds to alpha-2-delta subunits of voltage-gated calcium channels, reducing excitatory neurotransmitter release, while magnesium sulfate acts as an NMDA receptor antagonist. Together, they provide synergistic analgesic effects that can reduce opioid requirements after surgery.
- Other names
- Pregabalin & Magnesium sulphate
02
Targets
NMDAR (Glutamate receptor ionotropic, NMDA)CACNA2D1 (Voltage-gated calcium channel subunit alpha2/delta-1)
Beyond the preview
Go deeper on pregabalin + magnesium sulfate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pregabalin + magnesium sulfate.